Consistent with this notion are findings reported in previous studies, where Meflin+ fibroblasts were found to suppress cancer progression and fibrosis in pancreatic cancer and cardiac and lung fibrosis, respectively, and were distinct from α-SMA+ myofibroblasts that promote disease progression30,32,36. This evidence concerns the gene ISLR and familial pancreatic carcinoma.